

# **Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) & Region - Global Forecast to 2028**

<https://marketpublishers.com/r/P8281B810034EN.html>

Date: September 2023

Pages: 234

Price: US\$ 4,950.00 (Single User License)

ID: P8281B810034EN

## **Abstracts**

The precision medicine market is expected to reach USD 50.2 billion by 2028 from USD 29.1 billion in 2023, at a CAGR of 11.5% during the forecast period. The key factors driving the growth of the precision medicine market include growing initiatives related to genomic research, and increasing number of regulatory approvals for personalized therapeutics. Moreover, rising demand for cell and gene therapies is an opportunity area for this market.

The precision medicine market has been segmented based on type, indication, end user and region.

“By type, the monoclonal antibodies segment accounted for the second largest share of the precision medicine market”

Based on type, the precision medicine market is categorized into inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. In 2022, monoclonal antibodies accounted for the highest growth rate owing to factors such as benefits offered by monoclonal antibodies over traditional medicines. These advantages have led to shifting focus of the clinical pipeline dominantly on monoclonal antibodies.

“By end user, the hospitals and clinics segment accounted for the largest share in the precision medicine market”

Based on end user, the precision medicine market is segmented into hospitals and clinics and home care settings. In 2022, the hospitals and clinics segment accounted for a largest share of the precision medicine market. Growth in this market segment can be attributed to availability of services such as genetic testing, diagnostics and counselling in hospital setups. Besides, hospitals have easy accessibility of therapeutic products which are made available for patients opting for precision medicine regime.

“North America: the largest share of the precision medicine market”

North America accounted for the largest share of the precision medicine market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering precision medicines, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market.

“Europe: The fastest-growing region in the precision medicine market.”

The Europe precision medicine market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for precision medicine advancements with presence of some of the key players in the market. Some examples of these players include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), GlaxoSmithKline plc (UK) among others.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, Directors- 30%, and Executives - 25%

By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 2.5% & Africa- 2.5%

## Prominent Players

F. Hoffmann-La Roche Ltd. (Switzerland)

Novartis AG (Switzerland)

Pfizer Inc. (US)

Bristol Myers Squibb (US)

AstraZeneca (UK)

Gilead Sciences, Inc. (US)

AbbVie Inc. (US)

Eli Lilly and Company (US)

GlaxoSmithKline plc (UK)

Sanofi (France)

Johnson & Johnson (US)

Merck KGaA (Germany)

Amgen, Inc. (US)

Takeda Pharmaceutical Company Limited (Japan)

Regeneron Pharmaceuticals, Inc. (US)

Sarepta Therapeutics, Inc. (US)

bluebird bio, Inc. (US)

Immunocore Holdings Plc (UK)

Blueprint Medicines Corporation (US)

Vertex Pharmaceuticals Incorporated (US)

Horizon Therapeutics Plc (Ireland)

Anylam Pharmaceuticals, Inc. (US)

Rigel Pharmaceuticals, Inc. (US)

Taiho Pharmaceutical Co., Ltd. (Japan)

Seagen Inc. (US)

#### Research Coverage:

This report provides a detailed picture of the precision medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the precision medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers”

Analysis of key drivers (growth in genomic research, genetic testing and companion diagnostics), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with precision medicines adoption) influencing the growth of the precision medicine market.

Product Development/ Innovation: Detailed insights on upcoming technologies,

research and development activities, and new product launches in the precision medicine market.

**Market Development:** Comprehensive information about lucrative markets- the report analyses the precision medicine market across varied regions.

**Market Diversification:** Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the precision medicine market.

**Competitive Assessment:** In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK), Pfizer Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), , GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US), Takeda Pharmaceutical Company Limited (Japan) among others in the precision medicine market.

## Contents

### 1 INTRODUCTION

#### 1.1 STUDY OBJECTIVES

#### 1.2 MARKET DEFINITION

##### 1.2.1 INCLUSIONS AND EXCLUSIONS

#### 1.3 MARKET SCOPE

##### 1.3.1 MARKETS COVERED

#### FIGURE 1 PRECISION MEDICINE MARKET SEGMENTATION

##### 1.3.2 YEARS CONSIDERED

#### 1.4 CURRENCY CONSIDERED

#### 1.5 LIMITATIONS

#### 1.6 STAKEHOLDERS

##### 1.6.1 RECESSION IMPACT

### 2 RESEARCH METHODOLOGY

#### 2.1 RESEARCH DATA

#### FIGURE 2 RESEARCH DESIGN

##### 2.1.1 SECONDARY DATA

##### 2.1.2 PRIMARY DATA

#### FIGURE 3 PRECISION MEDICINE MARKET: BREAKDOWN OF PRIMARIES

#### 2.2 MARKET SIZE ESTIMATION

#### FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS

#### FIGURE 5 MARKET SIZE ESTIMATION FOR PRECISION MEDICINE: REVENUE SHARE ANALYSIS

##### 2.2.1 INSIGHTS FROM PRIMARIES

#### FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS

##### 2.2.2 SEGMENT ASSESSMENT (BY TYPE, INDICATION, AND END USER)

#### FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

#### 2.3 GROWTH FORECAST

#### FIGURE 8 PRECISION MEDICINE MARKET: CAGR PROJECTIONS

#### FIGURE 9 PRECISION MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

#### 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION

#### FIGURE 10 DATA TRIANGULATION METHODOLOGY

#### 2.5 RESEARCH ASSUMPTIONS

#### 2.6 RISK ANALYSIS

## 2.7 RECESSION IMPACT ANALYSIS

TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)

## 3 EXECUTIVE SUMMARY

FIGURE 11 PRECISION MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 12 PRECISION MEDICINE MARKET, BY INDICATION, 2023 VS. 2028

FIGURE 13 PRECISION MEDICINE MARKET, BY END USER, 2023 VS. 2028

FIGURE 14 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET

## 4 PREMIUM INSIGHTS

### 4.1 PRECISION MEDICINE MARKET OVERVIEW

FIGURE 15 INCREASING REGULATORY APPROVALS FOR PRECISION MEDICINES TO DRIVE MARKET

### 4.2 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE AND COUNTRY

FIGURE 16 INHIBITOR DRUGS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA (2022)

### 4.3 PRECISION MEDICINE MARKET, BY INDICATION

FIGURE 17 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

### 4.4 PRECISION MEDICINE MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES

FIGURE 18 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

## 5 MARKET OVERVIEW

### 5.1 INTRODUCTION

### 5.2 MARKET DYNAMICS

FIGURE 19 PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

#### 5.2.1 DRIVERS

5.2.1.1 Growing focus on genomic research

TABLE 2 INITIATIVES IN GENOMIC RESEARCH AND PRECISION MEDICINE

5.2.1.2 Growth in genetic testing and companion diagnostics

5.2.1.3 Increasing regulatory approvals for personalized therapeutics

#### 5.2.2 RESTRAINTS

5.2.2.1 High costs of therapeutic development

### 5.2.3 OPPORTUNITIES

5.2.3.1 Rising demand for cell and gene therapies

### 5.2.4 CHALLENGES

5.2.4.1 Challenges associated with adoption of precision medicine

## 5.3 PORTER'S FIVE FORCES ANALYSIS

### TABLE 3 PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS

5.3.1 THREAT OF NEW ENTRANTS

5.3.2 THREAT OF SUBSTITUTES

5.3.3 BARGAINING POWER OF SUPPLIERS

5.3.4 BARGAINING POWER OF BUYERS

5.3.5 INTENSITY OF COMPETITIVE RIVALRY

## 5.4 TECHNOLOGY ANALYSIS

## 5.5 VALUE CHAIN ANALYSIS

### FIGURE 20 PRECISION MEDICINE MARKET: VALUE CHAIN

5.5.1 RESEARCH & DEVELOPMENT

5.5.2 MANUFACTURING

5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES ACTIVITIES

## 5.6 ECOSYSTEM ANALYSIS

### FIGURE 21 PRECISION MEDICINE MARKET: ECOSYSTEM MAP

## 5.7 PATENT ANALYSIS

### FIGURE 22 PATENT APPLICATIONS FOR PRECISION MEDICINE THERAPEUTIC PRODUCTS (JANUARY 2012–JULY 2023)

### TABLE 4 PRECISION MEDICINE MARKET: INDICATIVE LIST OF PATENTS

## 5.8 PIPELINE ANALYSIS

### TABLE 5 PRECISION MEDICINE THERAPEUTICS IN CLINICAL PIPELINE

## 5.9 SUPPLY CHAIN ANALYSIS

5.9.1 PROMINENT COMPANIES

5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES

5.9.3 END USERS

5.9.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES

5.9.5 REGULATORY BODIES

### FIGURE 23 PRECISION MEDICINE THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS

### TABLE 6 PRECISION MEDICINE MARKET: SUPPLY CHAIN ECOSYSTEM

## 5.10 REGULATORY ANALYSIS

### TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

### TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS



TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.11 PRICING ANALYSIS

5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS

TABLE 11 AVERAGE SELLING PRICE OF PRECISION MEDICINE THERAPEUTICS

5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.13 KEY CONFERENCES AND EVENTS

TABLE 12 PRECISION MEDICINE MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024)

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRECISION MEDICINE THERAPEUTICS IN HOSPITALS AND CLINICS

5.14.2 BUYING CRITERIA FOR PRECISION MEDICINE MARKET

FIGURE 25 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS

## **6 PRECISION MEDICINE MARKET, BY TYPE**

6.1 INTRODUCTION

TABLE 13 PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

6.2 INHIBITOR DRUGS

6.2.1 ADVANTAGES OF HIGH ACCURACY AND AFFORDABILITY TO DRIVE MARKET

TABLE 14 APPROVED INHIBITOR DRUGS IN PRECISION MEDICINE MARKET (2022)

TABLE 15 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2021–2028 (USD MILLION)

TABLE 16 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 17 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 18 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)

6.3 MONOCLONAL ANTIBODIES

6.3.1 HIGH SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET

TABLE 19 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY

REGION, 2021–2028 (USD MILLION)

TABLE 20 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 21 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 22 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

#### 6.4 CELL AND GENE THERAPY

6.4.1 WIDE APPLICATIONS IN ONCOLOGY THERAPEUTICS TO FUEL MARKET

TABLE 23 PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)

TABLE 24 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 25 EUROPE: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 26 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)

#### 6.5 ANTIVIRAL AND ANTIRETROVIRAL DRUGS

6.5.1 MINIMAL SIDE EFFECTS DUE TO TARGETED APPROACH TO SUPPORT MARKET GROWTH

TABLE 27 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY REGION, 2021–2028 (USD MILLION)

TABLE 28 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 29 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 30 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)

#### 6.6 OTHER THERAPEUTIC PRODUCTS

TABLE 31 PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2021–2028 (USD MILLION)

TABLE 32 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 33 EUROPE: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 34 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)

## 7 PRECISION MEDICINE MARKET, BY INDICATION

## 7.1 INTRODUCTION

TABLE 35 PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

## 7.2 ONCOLOGY

7.2.1 INCREASING PRODUCT APPROVALS FOR CANCER THERAPEUTICS TO DRIVE MARKET

TABLE 36 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 37 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 38 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 39 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

## 7.3 RARE DISEASES

7.3.1 GROWING FOCUS ON PRODUCT DEVELOPMENT TO DRIVE MARKET

TABLE 40 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 41 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 42 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 43 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

## 7.4 INFECTIOUS DISEASES

7.4.1 RISING INCIDENCE OF HIV AND TB TO FUEL MARKET

TABLE 44 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 45 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 46 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 47 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

## 7.5 HEMATOLOGICAL DISORDERS

7.5.1 INCREASING CASES OF SICKLE CELL DISEASE AND ANEMIA TO SUPPORT MARKET GROWTH

TABLE 48 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS,

BY REGION, 2021–2028 (USD MILLION)

TABLE 49 NORTH AMERICA: PRECISION MEDICINE MARKET FOR

HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 50 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL

DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 51 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL

DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)

7.6 OTHER INDICATIONS

TABLE 52 PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY

REGION, 2021–2028 (USD MILLION)

TABLE 53 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER

INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 54 EUROPE: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS,

BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 55 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER

INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

## **8 PRECISION MEDICINE MARKET, BY END USER**

8.1 INTRODUCTION

TABLE 56 PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

8.2 HOSPITALS AND CLINICS

8.2.1 WIDE ADOPTION OF PRECISION MEDICINE FOR COMPLEX MEDICAL PROCEDURES TO DRIVE MARKET

TABLE 57 PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)

TABLE 58 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 59 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 60 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)

8.3 HOME CARE SETTINGS

8.3.1 ADVANTAGES OF PATIENT COMFORT AND REDUCED HOSPITAL STAYS TO SUPPORT MARKET GROWTH

TABLE 61 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)

TABLE 62 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE

SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 63 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE

SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 64 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE

SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)

## **9 PRECISION MEDICINE MARKET, BY REGION**

### 9.1 INTRODUCTION

TABLE 65 PRECISION MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION)

### 9.2 NORTH AMERICA

FIGURE 26 NORTH AMERICA: PRECISION MEDICINE MARKET SNAPSHOT

TABLE 66 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 67 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 68 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 69 NORTH AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.2.1 US

9.2.1.1 Rising regulatory approvals for therapeutic products to drive market

TABLE 70 PERSONALIZED MEDICINE PRODUCT APPROVALS BY US FDA

TABLE 71 US: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 72 US: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 73 US: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.2.2 CANADA

9.2.2.1 Rising incidence of cancer to drive market

TABLE 74 CANADA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 75 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 76 CANADA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.2.3 NORTH AMERICA: RECESSION IMPACT

### 9.3 EUROPE

**FIGURE 27 EUROPE: PRECISION MEDICINE MARKET SNAPSHOT****TABLE 77 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)****TABLE 78 EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)****TABLE 79 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)****TABLE 80 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)****9.3.1 GERMANY****9.3.1.1 Rising R&D initiatives for therapeutics to drive market****TABLE 81 GERMANY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)****TABLE 82 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)****TABLE 83 GERMANY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)****9.3.2 UK****9.3.2.1 Rising incidence of hematologic cancers to drive market****TABLE 84 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040****TABLE 85 UK: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)****TABLE 86 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)****TABLE 87 UK: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)****9.3.3 FRANCE****9.3.3.1 Increasing initiatives in genomic research to drive market****TABLE 88 FRANCE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)****TABLE 89 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)****TABLE 90 FRANCE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)****9.3.4 ITALY****9.3.4.1 Growing awareness initiatives for personalized treatment to propel market****TABLE 91 ITALY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)****TABLE 92 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028**



(USD MILLION)

TABLE 93 ITALY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.3.5 SPAIN

9.3.5.1 Rising funding initiatives for cell and gene therapies to support market growth

TABLE 94 SPAIN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 95 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 96 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.3.6 REST OF EUROPE

TABLE 97 REST OF EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 98 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 99 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.3.7 EUROPE: RECESSION IMPACT

### 9.4 ASIA PACIFIC

TABLE 100 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 102 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 103 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.4.1 CHINA

9.4.1.1 High incidence of chronic diseases and large patient volume to fuel market

TABLE 104 CHINA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 105 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 106 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.4.2 JAPAN

9.4.2.1 Availability of reimbursements for medical procedures to support market growth

TABLE 107 JAPAN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 108 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 109 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.4.3 INDIA

9.4.3.1 Rising burden of chronic diseases to drive market

TABLE 110 INDIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 111 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 112 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.4.4 AUSTRALIA

9.4.4.1 Rising R&D projects for genomic sequencing to propel market

TABLE 113 AUSTRALIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 114 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 115 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.4.5 REST OF ASIA PACIFIC

TABLE 116 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 117 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 118 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

#### 9.4.6 ASIA PACIFIC: RECESSION IMPACT

### 9.5 LATIN AMERICA

9.5.1 INVESTMENTS IN PRECISION MEDICINE DIAGNOSTICS TO SUPPORT MARKET GROWTH

TABLE 119 LATIN AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 120 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 121 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)



## 9.5.2 LATIN AMERICA: RECESSION IMPACT

## 9.6 MIDDLE EAST

### 9.6.1 RISING AWARENESS OF INNOVATIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH

TABLE 122 MIDDLE EAST: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 123 MIDDLE EAST: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 124 MIDDLE EAST: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

## 9.7 AFRICA

### 9.7.1 INCREASING COLLABORATIVE EFFORTS WITH ESTABLISHED COUNTRIES FOR PRECISION DIAGNOSTICS TO SUPPORT MARKET GROWTH

TABLE 125 AFRICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 126 AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 127 AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)

## 9.8 MIDDLE EAST & AFRICA: RECESSION IMPACT

# 10 COMPETITIVE LANDSCAPE

## 10.1 OVERVIEW

### 10.1.1 STRATEGIES ADOPTED BY KEY PLAYERS

## 10.2 MARKET SHARE ANALYSIS

FIGURE 28 PRECISION MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)

TABLE 128 PRECISION MEDICINE MARKET: INTENSITY OF COMPETITIVE RIVALRY

## 10.3 REVENUE SHARE ANALYSIS

FIGURE 29 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2020?2022)

## 10.4 COMPANY EVALUATION MATRIX

FIGURE 30 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (2022)

### 10.4.1 STARS

### 10.4.2 PERVASIVE PLAYERS

### 10.4.3 EMERGING LEADERS

### 10.4.4 PARTICIPANTS

## 10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES

### FIGURE 31 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)

#### 10.5.1 PROGRESSIVE COMPANIES

#### 10.5.2 STARTING BLOCKS

#### 10.5.3 DYNAMIC COMPANIES

#### 10.5.4 RESPONSIVE COMPANIES

## 10.6 COMPETITIVE BENCHMARKING OF LEADING PLAYERS

### 10.6.1 PRODUCT FOOTPRINT OF COMPANIES

#### TABLE 129 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS

### 10.6.2 REGIONAL FOOTPRINT OF COMPANIES

#### TABLE 130 PRECISION MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS

## 10.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES

#### TABLE 131 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES

#### TABLE 132 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES

## 10.8 COMPETITIVE SCENARIO AND TRENDS

### 10.8.1 PRODUCT APPROVALS

#### TABLE 133 PRECISION MEDICINE MARKET: PRODUCT APPROVALS (JANUARY 2020?JUNE 2023)

### 10.8.2 DEALS

#### TABLE 134 PRECISION MEDICINE MARKET: DEALS (JANUARY 2020?JUNE 2023)

### 10.8.3 OTHER DEVELOPMENTS

#### TABLE 135 PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS (JANUARY 2020?JULY 2023)

## 11 COMPANY PROFILES

(Business overview, Products offered, Recent Developments, MNM view)\*

### 11.1 KEY PLAYERS

#### 11.1.1 F. HOFFMANN-LA ROCHE LTD.

#### TABLE 136 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW

#### FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)

#### TABLE 137 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS

#### 11.1.2 BRISTOL MYERS SQUIBB

#### TABLE 138 BRISTOL MYERS SQUIBB: COMPANY OVERVIEW

#### FIGURE 33 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2022)

#### TABLE 139 BRISTOL MYERS SQUIBB: DEALS

#### TABLE 140 BRISTOL MYERS SQUIBB: PRODUCT APPROVALS

### 11.1.3 NOVARTIS AG

TABLE 141 NOVARTIS AG: COMPANY OVERVIEW

FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022)

TABLE 142 NOVARTIS AG: DEALS

TABLE 143 NOVARTIS AG: PRODUCT APPROVALS

### 11.1.4 GILEAD SCIENCES, INC.

TABLE 144 GILEAD SCIENCES, INC.: COMPANY OVERVIEW

FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)

TABLE 145 GILEAD SCIENCES, INC.: DEALS

TABLE 146 GILEAD SCIENCES, INC.: PRODUCT APPROVALS

### 11.1.5 ASTRAZENECA

TABLE 147 ASTRAZENECA: COMPANY OVERVIEW

FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2022)

TABLE 148 ASTRAZENECA: DEALS

TABLE 149 ASTRAZENECA: PRODUCT APPROVALS

### 11.1.6 ABBVIE INC.

TABLE 150 ABBVIE INC.: COMPANY OVERVIEW

FIGURE 37 ABBVIE INC.: COMPANY SNAPSHOT (2022)

TABLE 151 ABBVIE INC.: DEALS

### 11.1.7 ELI LILLY AND COMPANY

TABLE 152 ELI LILLY AND COMPANY: COMPANY OVERVIEW

FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)

TABLE 153 ELI LILLY AND COMPANY: DEALS

TABLE 154 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS

### 11.1.8 SAREPTA THERAPEUTICS, INC.

TABLE 155 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW

FIGURE 39 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)

TABLE 156 SAREPTA THERAPEUTICS, INC.: DEALS

TABLE 157 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS

TABLE 158 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS

### 11.1.9 PFIZER INC.

TABLE 159 PFIZER INC.: COMPANY OVERVIEW

FIGURE 40 PFIZER INC.: COMPANY SNAPSHOT (2022)

TABLE 160 PFIZER INC.: DEALS

TABLE 161 PFIZER INC.: PRODUCT APPROVALS

TABLE 162 PFIZER INC.: OTHER DEVELOPMENTS

### 11.1.10 GLAXOSMITHKLINE PLC

TABLE 163 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW

FIGURE 41 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)

TABLE 164 GLAXOSMITHKLINE PLC: DEALS

TABLE 165 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS

11.1.11 SANOFI

TABLE 166 SANOFI: COMPANY OVERVIEW

FIGURE 42 SANOFI: COMPANY SNAPSHOT (2022)

TABLE 167 SANOFI: DEALS

TABLE 168 SANOFI: PRODUCT APPROVALS

11.1.12 JOHNSON & JOHNSON

TABLE 169 JOHNSON & JOHNSON: COMPANY OVERVIEW

FIGURE 43 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)

TABLE 170 JOHNSON & JOHNSON: PRODUCT APPROVALS

11.1.13 BLUEBIRD BIO, INC.

TABLE 171 BLUEBIRD BIO, INC.: COMPANY OVERVIEW

FIGURE 44 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)

TABLE 172 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES

TABLE 173 BLUEBIRD BIO, INC.: PRODUCT APPROVALS

11.1.14 MERCK KGAA

TABLE 174 MERCK KGAA: COMPANY OVERVIEW

FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)

TABLE 175 MERCK KGAA: PRODUCT APPROVALS

11.1.15 AMGEN, INC.

TABLE 176 AMGEN, INC.: COMPANY OVERVIEW

FIGURE 46 AMGEN, INC.: COMPANY SNAPSHOT (2022)

TABLE 177 AMGEN, INC.: DEALS

TABLE 178 AMGEN, INC.: PRODUCT APPROVALS

11.1.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED

TABLE 179 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW

FIGURE 47 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)

TABLE 180 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS

11.1.17 REGENERON PHARMACEUTICALS, INC.

TABLE 181 REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW

FIGURE 48 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)

TABLE 182 REGENERON PHARMACEUTICALS, INC.: DEALS

TABLE 183 REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS

11.1.18 IMMUNOCORE LTD.

TABLE 184 IMMUNOCORE LTD.: COMPANY OVERVIEW  
FIGURE 49 IMMUNOCORE LTD.: COMPANY SNAPSHOT (2022)  
TABLE 185 IMMUNOCORE LTD.: DEALS  
TABLE 186 IMMUNOCORE LTD.: PRODUCT APPROVALS  
11.1.19 BLUEPRINT MEDICINES CORPORATION  
TABLE 187 BLUEPRINT MEDICINES CORPORATION: COMPANY OVERVIEW  
FIGURE 50 BLUEPRINT MEDICINE: COMPANY SNAPSHOT (2022)  
TABLE 188 BLUEPRINT MEDICINES CORPORATION: DEALS  
TABLE 189 BLUEPRINT MEDICINES CORPORATION: PRODUCT APPROVALS  
11.2 OTHER PLAYERS  
11.2.1 VERTEX PHARMACEUTICALS INCORPORATED  
11.2.2 MIRATI THERAPEUTICS, INC  
11.2.3 ARGENX SE  
11.2.4 HORIZON THERAPEUTICS PLC  
11.2.5 BRIDGEBIO PHARMA, INC.  
11.2.6 TREVENA, INC.  
11.2.7 INCYTE CORPORATION  
11.2.8 ALNYLAM PHARMACEUTICALS, INC.  
11.2.9 RIGEL PHARMACEUTICALS, INC.  
11.2.10 TAIHO PHARMACEUTICAL CO., LTD (PART OF OTSUKA HOLDINGS CO., LTD.)  
11.2.11 AGIOS PHARMACEUTICALS, INC.  
11.2.12 SEAGEN, INC.  
11.2.13 RHYTHM PHARMACEUTICALS, INC.  
11.2.14 MACROGENICS, INC.

\*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

## **12 APPENDIX**

12.1 DISCUSSION GUIDE  
12.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL  
12.3 CUSTOMIZATION OPTIONS  
12.4 RELATED REPORTS  
12.5 AUTHOR DETAILS

## I would like to order

Product name: Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) & Region - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/P8281B810034EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8281B810034EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970